MacroGenics, Inc. will get a significant infusion of cash in its newly announced deal with Gilead Sciences, Inc. focused on MagroGenics’ Phase I CD123-targeting bispecific antibody program. It’s also an important nod for its next-generation CD123 candidate, after it discontinued a first-generation program with the same target.
Deal With Gilead For Anti-CD123 Bispecific Offers Breath Of Fresh Air For MacroGenics
MacroGenics believes its next-gen anti-CD123 candidate MGD024 has a potentially favorable toxicity profile, as other bispecifics with the same target have floundered. But it lacks the cash to advance on its own.
